You just read:

Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy

News provided by

Ionis Pharmaceuticals, Inc.

Jan 12, 2016, 07:00 ET